Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 8/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7964051 | 0.82 | CCR1 (0.52) | CCR1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL7967897 | 0.79 | GLA (0.44) | GLAGAADRD2ADRA1ALMNA | |
| SCHEMBL7961380 | 0.78 | DRD2 (0.54) | CCR1DRD2ADRA1A | |
| SCHEMBL7960233 | 0.78 | CCR1 (0.54) | CCR1DRD2ADRA1A | |
| SCHEMBL7960074 | 0.78 | DRD2 (0.62) | CCR1DRD2ADRA1A | |
| SCHEMBL7949619 | 0.78 | DRD2 (0.53) | CCR1OPRM1OPRK1DRD2ADRA1A | |
| SCHEMBL7949530 | 0.77 | DRD2 (0.56) | CCR1DRD2ADRA1A | |
| SCHEMBL7959852 | 0.77 | KDM4E (0.47) | CCR1OPRL1DRD2ADRA1A | |
| SCHEMBL7957164 | 0.77 | DRD2 (0.56) | CCR1DRD2 | |
| SCHEMBL7963515 | 0.77 | CCR1 (0.58) | CCR1OPRL1DRD2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6187774-B1 | N-PIPERAZINYLALKYLINDAZOLE DERIVATIVES; PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0885883-A1 | FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |